Background/aims: We found that pooled Crohn's disease (CD) sera strongly react with a human gap-junction connexin 37 (Cx37) peptide and tested for anti-Cx37 antibody reactivity in sera from CD patients and controls. We also investigated whether peptide-recognition is due to Cx37/ microbial molecular mimicry. Methods: The PSI-BLAST program was used for Cx37 121-135 /microbial alignment. Reactivity to biotinylated human Cx37 121-135 and its microbial mimics was determined by ELISA using sera from 44 CD, 30 ulcerative colitis and 28 healthy individuals. Results: Anti-Cx37 121-135 reactivity (1/200 dilution) was present in 30/44 (68%) CD cases and persisted at 1/1000 dilution. Database search shows that Cx37 121-135 contains the -ALTAV-motif
Introduction
Epidemiological, clinical, serological and experimental studies support the notion that immune-mediated intestinal destruction in Crohn's disease (CD) commences when genetically susceptible individuals are exposed to microbial stimulants, and that the microbial/host immune encounter is essential in triggering, initiating or modulating the course or outcome of this inflammatory bowel disease (IBD). [1] [2] [3] [4] [5] [6] [7] [8] [9] Accumulating evidence points to a role for microbial/self molecular mimicry as a mechanism to explain the involvement of microbial triggers in the immunopathogenesis of CD, but also as a tool to identify CD-specific autoantigens. 1, 6, 10, 11 We have previously reported that Mycobacterium avium subsp. paratuberculosis antigenic sequences and its mimicking intestinal antigens, such as gastrointestinal glutathione peroxidase, are specific targets of cross-reactive antibody responses in approximately 40% of patients with CD. 11 These findings have prompted us to apply a similar approach in an attempt to identify other self and microbial cross-reactive targets in patients with CD. 11 In a preliminary set of experiments, we have tested a pool of 5 CD sera to screen for antibody binding using as an antigenic source a large library of approximately 800 peptide spanning sequences from human and microbial peptidyl sequences, never tested before in CD sera. These peptides have been constructed over the last 12 years, and tested as microbial/self crossreactive targets in the Molecular Mimicry Project of Liver Immunopathology at King's College London. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] These studies included patients with various gastrointestinal, liver and extrahepatic autoimmune diseases such as insulindependent diabetes, autoimmune thyroiditis and multiple sclerosis. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] We have found a strong reactivity of the pooled CD sera against a peptide corresponding to connexin 37 kDa (Cx37), also known as gap junction alpha-4 protein. 25 Emerging data suggests that connexins contribute to the generation of diarrhoea during infectious enteric disease. 26 In addition, recent studies indicate that Cx37 and other connexins are expressed by various immune cell types, supporting an important role of these proteins in gap junction-mediated antigen transport and intercellular communication in the immune system. [27] [28] [29] With regard to Cx37, there is no published data to suggest that this connexin is a target of an autoimmune attack, or that it is involved in the immunopathogenesis of CD.
Nevertheless, a recent study demonstrated increased gene expression and altered protein expression of Cx37 in highly purified enterocytes with active coeliac disease, suggesting that this connexin may be involved in enterocyte-specific immunopathological processes. 30 On the basis of these emerging data, we have considered that Cx37's antibody recognition by pooled CD sera was worthy of a more detailed study. Intriguingly enough, the diabetes-specific phogrin peptide with a striking similarity (see later discussion) to Cx37 peptide, and included in the same peptide library, was totally unreactive, suggesting a Cx37-specific reactivity of the pooled CD sera.
The goal of the present study was to test for anti-Cx37-specific antibody responses in a well-defined population of CD patients. Having found that the great majority of these patients contain high-titres of anti-Cx37 antibodies, and that this peptide is highly homologous to phogrin and the phogrinmimicking microbial peptides previously implicated in the pathogenesis of insulin-dependent diabetes mellitus [31] [32] [33] [34] [35] [36] [37] , we have also assessed whether microbial and Cx37 peptides are targets of cross-reactivity antibody recognition in patients with CD.
Material and methods

Patients
Serum samples from 44 patients with CD (mean age 41, range 21-76 years, 23 female), attending the out-patient clinic of Hepatogastroenterology Unit, Attikon Hospital, University of Athens, Greece, were tested. The diagnosis of CD was based on clinical, endoscopic, radiological, and histological criteria. Table 1 summarizes the demographical and clinical characteristics of the patients enrolled in the study. Thirty five patients had ileocolonic disease, 8 had colonic disease and 1 had isolated small bowel disease. At the time of serum collection, 41 patients were on treatment (Table 1) , and 7 patients had undergone at least 1 surgery for CD. With regard to disease severity, 21 patients had quiescent disease, 2 had mild disease, 13 had moderate and 8 had severe disease as classified using the Harvey-Bradshaw activity index. 38 Demographically matched sera from 30 patients with well characterized UC (mean age 39, 39 ± 15.4 years, range, 19-79 years, 22 men) were included as pathologic controls.
All diagnoses of UC were supported by endoscopic and histologic findings. At the time of serum collection, 10 patients were on systemic steroid treatment (prednisolone), and 3 patients were on azathioprine.
Twenty-eight sera from healthy volunteer staff members (mean age, 38.2 ± 7.1 years; range, 19-52 years; 16 men) also were tested as normal controls.
Experimental work complied with the principles laid down in the Declaration of Helsinki. Participating individuals gave informed consent to the work.
The project was approved by the Attikon Hospital research ethics committee.
Protein database search and analysis
The computer-assisted protein sequence alignment Basic Local Alignment Search Tool (BLASTp) program (NCBI, BLAST server available at http://www.ncbi.nlm.nih.gov/BLAST, matrix: BLOSUM62) was used to search for microbial sequences that share with the human Cx37 121-135 , the -ALTAVE-motif or other related motifs as deposited in the nr protein database (EBI-EMBL, Cambridge, UK).
Three dimensional modelling
Three dimensional modelling of the human coxsackie B4 mimicking sequence was performed by analysing the corresponding known structure of the conserved human coxsackie B3 polyprotein (Molecular Modelling Database [MMDB] code: 17225; PDB:1JEW_1) using the Cn3D visualization tool (http://www.ncbi.nlm.nih.gov/Structure/CN3D/ cn3dtut.shtml).
Peptide construction
Ten 15-meric peptides containing human Cx37 121-135 and 9 mimicking peptides (Fig. 1) were synthesized commercially and supplied at N 75% purity (Mimotopes, Clayton, Victoria, Australia). A 15-meric peptide encoding a randomly generated sequence of amino acids (-YVNQSLRPTPLEISV-) was used as negative control peptide. 11, 39, 40 2.5. Anti-peptide antibody reactivity by ELISA Antibody binding to the peptides was determined by ELISA, as previously described. [11] [12] [13] [14] 22, 24, [40] [41] [42] [43] The optimal concentrations of reagents at various steps of the immunoassay were determined in preliminary experiments by checkerboard titration.
Serum samples were tested at various dilutions ranging from 1/100 to 1/100,000 to define the dilution giving the lowest background noise, and the optimal anti-peptide binding value. Similarly, different concentrations of individual peptides were tested (0.1, 1, 5 and 15 μg/ml). The optimal coating concentration for individual peptides was 5 μg/ml and the optimal serum dilution was 1/200. Absorbance (optical density) was read in a microplate reader (MRX; Dynex Technologies, West Sussex, UK) at 490 nm. On each plate, 2 wells were used as blanks in which serum and peptide were omitted, and 2 additional wells were used for positive and negative controls. The positive control consisted of a liver kidney microsomal type 1-positive serum (titre 1/ 10,240) from a patient with autoimmune hepatitis type 2, which in preliminary experiments was shown to react with the immunodominant liver kidney microsomal type 1 cytochrome P4502D6 (CYP2D6) 252-271 autoepitope. Coefficients of variation of the inter-assay and intra-assay coefficients of variation were less than 10%. Each serum tested against experimental peptides was also tested against the control peptide. Tests based on subtracted (from the irrelevant control peptide) optical densities avoid false-positive results owing to non-specific binding to unrelated peptides in hypergammaglobulinemic serum samples. 11, 12, 24 Anti-peptide reactivity of the sera was considered positive when the optical density of a given peptide (subtracted from that of the irrelevant control peptide) was N 0.19, a cut-off higher than the mean + 10 SD of the absorbance values of 90 readings against the control peptide using 45 randomly selected sera (15 CD, 15 UC and 15 normal controls) tested in duplicate.
Antibody reactivity to native human connexin 37
Reactivity to native human connexin 37 was tested by immunoblotting using a human whole cell lysate from colorectal adenocarcinoma cells (COLO 320DM, Santa Cruz Biotechnology Inc, Santa Cruz, California, USA). For immunoblotting, 20 μg COLO 320DM cell lysate was resolved in a 10% acrylamide mini-gel using 200 μl SDS-PAGE Western blotting buffer and then transferred onto a polyvinylidene fluoride (PVDF) membrane in a semi-dry electrophoretic transfer cell, in transfer buffer, at 25 V constant voltage for 2 h. To inhibit non-specific reactivity, the strips were incubated with blocking buffer (5% skimmed milk in PBS 0.1% Tween 20) for 1 h at room temperature and were immunoblotted for 2 h at room temperature with individual sera (dilution 1/200) from 12 anti-Cx37 121-135 antibody positive sera (8 CD, 2 UC and 2 healthy controls) and 8 Cx37 121-135 antibody negative sera (5 CD and 2 UC and 1 healthy control). A purified rabbit polyclonal antibody specific for human connexin 37 raised using as an immunogen a polypeptidyl sequence corresponding to aa 108-157 of the protein (Abcam, Cambridge, UK) was used as a positive control. Washing followed by the addition of goat horse radish peroxidase-conjugated anti-human IgG (1/5000) for the serum samples or anti-rabbit IgG (1/10,000) for the polyclonal anti-Cx37 antibody for 1 h at room temperature. The reaction was detected using a non-radioactive enhanced chemiluminescent system and developed on an X-OMAT film.
Inhibition studies
Reactive peptides were used as solid phase inhibitors to absorb out anti-specific antibody reactivity, as previously described. 12, 14, [42] [43] [44] [45] Briefly, 200 μl of individual microbial and human Cx37 121-135 double reactive sera (n = 5) diluted 1/ 500 were added to the first well of an ELISA plate pre-coated with individual peptides at final concentration of 15 μg/ml. After 20 min incubation at room temperature, the serum was sequentially transferred to wells 2-12 (pre-coated with the same antigenic preparation), with a 20-minute incubation in each well. The same experiments were carried out for each of the reactive peptides and the control peptide or PBS alone. One hundred microliters of absorbed serum were then tested for reactivity against Cx37 121-135 or the microbial mimics by ELISA, and was compared with reactivity before absorption.
Statistical analysis
Results are presented as the mean ± standard deviation (SD) or as percentages. Comparisons between categoric values were made using the t test, χ 2 test or the Fisher exact as appropriate. Correlations between variables were assessed using the Pearson's correlation coefficient. A 2-tailed P value of less than 0.05 was considered significant. Statistical analyses were performed using SPSS (SPSS Inc., Chicago, IL) statistical package.
Results
Amino acid alignment
BLAST search revealed that Cx37 121-135 is the only human sequence which contains the 6 amino acid motif -ALTAVE-. The ALTAV motif is a core epitopic region previously described as the focus of immune cross-recognition by the human phogrin beta cell autoantigen-mimicking enteroviral epitopes. This has been implicated in the pathogenesis of insulin-dependent-diabetes. Cx37 121-135 shares 6 amino acids in a row (ALTAVE) with microbial mimics including human coxsackie A9 (aa 693-707), A24 (aa 618-632), B4 (aa 593-607), enterovirus C polyprotein (aa 614-628) and human poliovirus VP-1 capsid protein (aa 38-52) (Fig. 1) . Other sequences containing an -ALTAV-motif include those originating from poliovirus, rubella virus and Lactococcus lactis and the human phogrin diabetes autoantigen. Cx37 121-135 is also highly homologous with Mycobacterium tuberculosis (Fig. 1). 
Antibody reactivity to human connexin 37
Anti-Cx37 121-135 reactivity was present in 30/44 (68%) cases with CD (mean optical density (OD) 0.3 ± 0.14 SD at 1:200 serum dilution) (Fig. 2) . None of the CD sera reacted with the control peptide. Amongst Cx37 121-135 reactive sera, 8 randomly selected were tested for antibody binding at increasing dilutions. All reacted at 1/500 and 7 at 1/1000; anti-Cx37 121-135 was lost at 1/10,000 (Fig. 3). 3.3. Anti-peptide antibody reactivity to connexin 37 mimics Table 2 summarize the data of antibody reactivity to the synthetic peptides tested in serum samples from 44 CD patients; 30 (68%) reacted with human enterovirus C (mean OD ± SD:0.29 ± 0.13), 30 (68%) with L. lactis (0.3 ± 0.12), 28 (64%) with coxsackie virus A24 (0.3 ± 0.14), 25 (57%) with coxsackie virus B4 (0.32 ± 0.16) and 3 (6.8%) with coxsackie virus A9 (one with no reactivity to Cx37 121-135 ). No reactivity was found to the peptidyl sequences from poliovirus, rubella, and M. tuberculosis mimics or the beta cell human phogrin ( Fig. 2 and Table 2 ).
Overall (Table 2) There were no differences in biochemical, clinical or other parameters between CD patients with or without microbial/ human Cx37 double reactivity.
Inhibition studies
Inhibition results of anti-peptide antibody binding by preincubation with human Cx37 121-135 and two of the most reactive microbial mimics (coxsackie B4 or L. lactis) in 5 representative cases are shown in Fig. 4 . Antibody binding to human Cx37 121-135 was inhibited by 89-93% after preincubation with Cx37 121-135 ; by 79-88% after pre-incubation with coxsackie B4; by 85-90% after pre-incubation with L. lactis mimic as solid phase competitor in all 5 cases tested. The control peptide did not abolish reactivity to human Cx37 121-135 or the microbial mimics.
Anti-peptide reactivity and inhibition studies in pathological and normal controls
Reactivity to at least one Cx37-mimicking microbial mimic was present in 15/30 (50%) patients with UC (mean OD ± SD:0.28 ± 0.17) and in 16/28 (57%) of normal (0.29 ± 0.15) controls (p N 0.05). The most reactive microbial mimics in both groups were those of coxsackie virus A24 and L. lactis (50% for both), coxsackie virus B4 (43% for UC and 50% for healthy controls) and human enterovirus C (43% for UC and 46% for healthy controls). Prevalence and absorbance values of anti-peptide reactivity did not differ between CD and UC 
Antibody reactivity to native human connexin 37
All but one anti-human Cx37 121-135 reactive sera immunofixed a band of~37 kDa corresponding to human connexin 37 by immunoblot using colon adenocarcinoma cell lysate. The reactive sera included all CD (n = 2) and UC (n = 2) patients and one of the two healthy controls. Amongst the 8 (5 CD and 3 UC) Cx37 121-135 antibody negative cases, one CD serum immunofixed a 37 kDa band. Results of the immunobloting experiments of representative cases are shown in Fig. 5 .
Three dimensional modelling
Local sequence homology modelling of the human coxsackie B4 virus polyprotein, using as template the known homologous coxsackie B3 3D-model predicts that the human connexin 37 121-135 mimicking coxsackie B4 sequence is located in a solvent-accessible surface region of the protein (Fig. 6 ).
Discussion
We report evidence that antibody reactivity to a human Cx37 peptide is highly prevalent in patients with CD, being present in all but a few cases. The great majority of them also recognise microbial mimics from human enteroviruses and L. lactis. The prevalence of reactivity to these mimics (up to Figure 4 Antibody binding to human connexin 37 (Cx37) 121-135 from serum of 5 representative cases with Crohn's disease was inhibited after pre-incubation with human Cx37 121-135 but also after pre-incubation with the coxsackie B4 (CVB4) or the Lactococcus lactis (LACLA) mimics. Inhibition was determined by competition ELISA. Pre-incubation of serum with an irrelevant (control) peptide did not diminish anti-Cx37 antibody reactivity. Thridimensional prediction model of the amino acids from the human coxsackie B polyprotein mimic of human connexin 37 is presented in the form of space fill (yellow) and the remaining are seen as a wire worm backbone (purple/gray). Prediction analysis anticipates that the epitope is exposed on the surface of the molecule. Helix elements are green and strand elements are brown. The structure was analyzed with the Cn3D visualization tool. 68%) is higher than that reported for antibodies to Saccharomyces cerevisiae (ASCA), porin protein-C or other CD-serological markers, none of which seems to exceed a prevalence of 50%. 46 While the relevance of the present findings to the immunopathogenesis of CD is yet to be determined, some findings are intriguing and warrant further investigation.
Why human Cx37 is targeted by autoantibodies in CD is not clear. Cx37 belongs to the family of connexins, the proteins assembled into gap junction channels. Although connexins serve diverse functions, they are best known for their role in cell differentiation and proliferation. 25 These proteins are selectively expressed in monocytes, and current evidence suggests that they play an important role in mediating intracellular signalling by cells of the immune system, and participate in immunopathological inflammatory processes. 25, [27] [28] [29] A recent report based on a variety of techniques including microarray, real time PCR and immunohistochemical analysis demonstrated that connexin 37 is upregulated in enterocytes from patients with active coeliac disease, when compared to patients with treated coeliac disease, as well as controls. 30 The possible involvement of this protein in an immune-mediated gastrointestinal disease is intriguing and warrants further investigation. 30 Studies on atherosclerosis, a disease recently appreciated to have a strong autoimmune component to its pathogenesis, clearly demonstrate that Cx37 expression changes location as the disease progresses, and this reallocation influences the outcome of the disease. [47] [48] [49] [50] [51] [52] This was also the case in a murine model of asthma where it has been shown that Cx37 is localized in epithelial layers around the bronchioles before the onset of the disease but disappears in allergen-induced asthmatic lungs. 53 Whether altered Cx37 expression, (especially at sites making it accessible to antibodies) provides the initial stimulus for the induction of an autoimmune response against this specific protein needs to be determined.
Interestingly, antibody reactivity was not limited to Cx37 121-135 but also included four of its nine microbial mimics, and in particular those originating from the enteroviruses coxsackie B4, A24 and C and one from L. lactis ( Fig. 1 and Table 2 ). The fact that the reactive peptides share with Cx37 the -ALTAV-motif implies that microbial sequences with this motif are highly immunogenic, and induce anti-self responses by virtue of molecular mimicry with self-antigens, such as phogrin in the case of diabetes or Cx37 in Crohn's disease. Indeed, three dimensional prediction analysis (Fig. 6) clearly indicates that corresponding mimicking sequences such as that of coxsackie virus B4 are exposed to the surface of the molecule, a finding compatible with antibody recognition. None of the CD sera, however, reacted with the -ALTAV-containing phogrin autoepitopic region. Moreover, rubella, poliovirus and M. tuberculosis mimics were totally unreactive while reactivity to coxsackie virus A9 was found only in few cases (Fig. 2) .
Collectively these data indicate that some of the observed reactivities are peptide/microbial-specific, and that the presence of the -ALTAV-motif per se is not sufficient for antibody binding. An explanation might lie in different patients having a different history of microbial exposure, leading to a case-specific reactivity to different outlying residues, in addition to the core -ALTAV-epitope. In support of this is the finding of a case-by-case pattern and magnitude of reactivity to the respective peptides (Table 2) . Certainly, the inhibition patterns and dissimilar proportion of absorbed reactivities for the five representative cases (Fig. 4) do suggest that relative reactivity is peptide-specific and not exactly the same for each serum.
Those concluding that responses to microbial mimics are irrelevant to disease pathogenesis because they appear to react in patients and controls need to take into account that the Cx37/phogrin-mimicking microbial peptides injected in animals are able to induce autoimmune responses to their phogrin mimic, as well as the full-length phogrin antigen. 31, 32 This has been demonstrated to induce pancreatic beta cell destruction indistinguishable from that seen in patients with insulin-dependent diabetes mellitus. 31, 32 Interestingly, pancreatic autoantibodies directed against the major zymogen granule membrane glycoprotein 2 are frequently seen in patients with CD. 54 GP2 autoantibodies appear to be directed against conformational epitopes while anti-Cx37 antibodies recognise a short linear sequence of the protein. 54 Epitope mapping studies based on overlapping peptides and mammalian expressed polypeptidyl constructs are needed to identify most of the (linear or conformational) epitopes that are recognized by Cx37-specific antibodies. This investigation will facilitate a better understanding of the potential pathogenic role of microbial/Cx37 molecular mimicry in CD. The fact that sera reacting with native human Cx37 in immunoblot experiments also react with Cx37 121-135 (Fig. 5) clearly indicates that this short sequence is an immunodominant epitope.
In relation to Cx37, antibody responses were less prevalent in pathological (UC patients) and healthy controls compared to CD patients, but this did not reach statistical significance. Our inability to inhibit reactivity to Cx37 by the microbial mimics in three of the 5 control cases tested is intriguing and may suggest microbial/self reactivity may be cross-reactive in CD cases but not in Cx37/microbial double reactive controls. This and other antibody characteristics, such as the IgG subclass distribution, may set CD sera apart from the other groups. These characteristics have not yet been explored.
Despite the lack of disease specificity, cross-reactive immune responses to microbial/human connexin 37 homologues may indeed be pathogenetically meaningful but only in those genetically susceptible individuals who are prone to develop autoimmune disease because of impaired safe-guard mechanisms. Our findings require external validation in larger human studies and ideally in an appropriate animal model setting.
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